Back
Akero Therapeutics Vs. NovaBay Pharmaceuticals Industry Stock Comparison
Buy
73
AKRO
Akero Therapeutics
Last Price:
30.72
Seasonality Move:
23.52%
Sell
39
NBY
NovaBay Pharmaceuticals
Last Price:
0.75
Seasonality Move:
-14.63%
Buy
73
Akero Therapeutics (AKRO)
is a Buy
Is Akero Therapeutics a Buy, Sell or Hold?
- The current Akero Therapeutics [AKRO] share price is $31.73. The Score for AKRO is 73, which is 46% above its historic median score of 50, and infers lower risk than normal.
- AKRO is currently trading in the 70-80% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
39
NovaBay Pharmaceuticals (NBY)
is a Sell
Is NovaBay Pharmaceuticals a Buy, Sell or Hold?
- The current NovaBay Pharmaceuticals [NBY] share price is $0.65. The Score for NBY is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.
- NBY is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
AKRO Stock Price Chart
What is Akero Therapeutics's stock price today?
-
The Akero Therapeutics share price today is $31.73
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and AKRO is experiencing buying pressure, which is a positive indicator for future bullish movement.
NBY Stock Price Chart
What is NovaBay Pharmaceuticals's stock price today?
-
The NovaBay Pharmaceuticals share price today is $0.65
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and NBY is experiencing slight buying pressure.
AKRO Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.69 | Buy |
| Relative Strength Index (14 RSI): | 64.21 | Buy |
| Chaikin Money Flow: | 477806 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (28 - 30.34) | Buy |
| Bollinger Bands (100): | (23.84 - 28.68) | Buy |
NBY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.02 | Sell |
| Relative Strength Index (14 RSI): | 54.43 | Buy |
| Chaikin Money Flow: | 1495578 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (0.59 - 0.71) | Buy |
| Bollinger Bands (100): | (0.32 - 2) | Sell |
AKRO Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 29.99 | Buy |
| 20-day SMA: | 29.35 | Buy |
| 50-day SMA: | 27.94 | Buy |
| 200-day SMA: | 24.42 | Buy |
| 8-day EMA: | 30.01 | Buy |
| 20-day EMA: | 29.4 | Buy |
| 50-day EMA: | 28.11 | Buy |
| 200-day EMA: | 26.41 | Buy |
NBY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 0.59 | Buy |
| 20-day SMA: | 0.63 | Buy |
| 50-day SMA: | 0.58 | Buy |
| 200-day SMA: | 2.76 | Sell |
| 8-day EMA: | 0.6 | Buy |
| 20-day EMA: | 0.61 | Buy |
| 50-day EMA: | 0.75 | Sell |
| 200-day EMA: | 6.52 | Sell |
Akero Therapeutics Earnings Growth & AKRO Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.17 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.73 per share, and a decrease next year of $0.63 per share.
NovaBay Pharmaceuticals Earnings Growth & NBY Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.05 per share, a decrease next quarter of $0.00 per share, an increase this year of $78.20 per share, and an increase next year of $1.81 per share.
Akero Therapeutics Technical Analysis
| Oct 15 | Oct 16 | Oct 18 | Oct 21 | Oct 22 | Oct 23 | Oct 24 | Oct 25 | Oct 28 | Oct 29 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | ||||||||||
| 15 | 16 | 18 | 21 | 22 | 23 | 24 | 25 | 28 | 29 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
NovaBay Pharmaceuticals Technical Analysis
| Oct 15 | Oct 16 | Oct 18 | Oct 21 | Oct 22 | Oct 23 | Oct 24 | Oct 25 | Oct 28 | Oct 29 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | ||||||||||
| 15 | 16 | 18 | 21 | 22 | 23 | 24 | 25 | 28 | 29 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||